CN117157064A - 铜病症的治疗 - Google Patents

铜病症的治疗 Download PDF

Info

Publication number
CN117157064A
CN117157064A CN202280025441.XA CN202280025441A CN117157064A CN 117157064 A CN117157064 A CN 117157064A CN 202280025441 A CN202280025441 A CN 202280025441A CN 117157064 A CN117157064 A CN 117157064A
Authority
CN
China
Prior art keywords
copper
triethylenetetramine disuccinate
triethylenetetramine
article
fixed dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280025441.XA
Other languages
English (en)
Chinese (zh)
Inventor
J·福图纳克
G·库珀
M·库珀
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferrera New Zealand LLC
Original Assignee
Ferrera New Zealand LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrera New Zealand LLC filed Critical Ferrera New Zealand LLC
Publication of CN117157064A publication Critical patent/CN117157064A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Conductive Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280025441.XA 2021-03-05 2022-03-04 铜病症的治疗 Pending CN117157064A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163157539P 2021-03-05 2021-03-05
US63/157,539 2021-03-05
PCT/US2022/019025 WO2022187709A1 (en) 2021-03-05 2022-03-04 Treatment of copper disorders

Publications (1)

Publication Number Publication Date
CN117157064A true CN117157064A (zh) 2023-12-01

Family

ID=83115853

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280025441.XA Pending CN117157064A (zh) 2021-03-05 2022-03-04 铜病症的治疗

Country Status (7)

Country Link
US (2) US20220280451A1 (https=)
EP (1) EP4301350A4 (https=)
JP (1) JP2024509193A (https=)
CN (1) CN117157064A (https=)
AU (1) AU2022231038A1 (https=)
CA (1) CA3212016A1 (https=)
WO (1) WO2022187709A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118987254A (zh) * 2024-08-15 2024-11-22 沈阳药科大学 一种基于双金属纳米点-溶瘤病毒静脉递送系统及其制备方法和应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023255339A1 (en) * 2022-04-19 2024-12-05 Sasha A. PHILBERT Treatment of brain copper disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2875522A1 (en) * 2002-08-20 2004-03-04 Philera New Zealand Limited Dosage forms and related therapies
PT1778618E (pt) * 2004-07-19 2014-03-04 Philera New Zealand Ltd Síntese de trietilenotetraminas
WO2006104396A1 (en) * 2005-03-26 2006-10-05 Protemix Corporation Limited Pre-complexed copper antagonist compositions
CA3018698A1 (en) * 2005-11-09 2007-05-18 Philera New Zealand Limited Treatment of mitochondria-related diseases and improvement of age-related metabolic deficits
US20090093542A1 (en) * 2007-10-04 2009-04-09 Cooper Garth J S Copper antagonist compositions
WO2017049529A1 (en) * 2015-09-24 2017-03-30 Innolife Co., Ltd. A pharmaceutical composition comprising a copper chelating tetramine and the use thereof
WO2017213524A1 (en) * 2016-06-10 2017-12-14 Garth Cooper Treatment of neurodegenerative disorders
CA3143523A1 (en) * 2019-06-17 2020-12-24 Philera New Zealand Ltd. Combination treatments for central nervous system disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118987254A (zh) * 2024-08-15 2024-11-22 沈阳药科大学 一种基于双金属纳米点-溶瘤病毒静脉递送系统及其制备方法和应用

Also Published As

Publication number Publication date
US20250114312A1 (en) 2025-04-10
EP4301350A4 (en) 2025-04-09
WO2022187709A1 (en) 2022-09-09
CA3212016A1 (en) 2022-09-09
JP2024509193A (ja) 2024-02-29
US20220280451A1 (en) 2022-09-08
AU2022231038A1 (en) 2023-09-21
EP4301350A1 (en) 2024-01-10

Similar Documents

Publication Publication Date Title
US20230285351A1 (en) Methods of providing solriamfetol therapy to subjects with impaired renal function
US20250114312A1 (en) Treatment of copper disorders
CN104284665B (zh) 吡唑衍生物及其医药用途
CN111050764A (zh) β-羟基丁酸酯和丁二醇的S对映异构体及其使用方法
US11083700B2 (en) Butyrate salts for use in inflammatory diseases
US9925154B2 (en) Cysteamine in the treatment of fibrotic disease
EA028049B1 (ru) Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
JP2025066802A (ja) ウィルソン病を治療するためのビスコリンテトラチオモリブデート
KR20210038586A (ko) 집단에서 디아미노페노티아진(diaminophenothiazines)의 최적 투여량
Naseef et al. Therapeutic potential of induced iron depletion using iron chelators in Covid-19
KR20190031552A (ko) 디아미노페노티아진 (diaminophenothiazines)의 투여 및 투여량 (dosage)
CN108289870A (zh) 治疗特定患者群体的神经变性病症的方法
US11458141B2 (en) Aryl hydrocarbon receptor (AhR) agonists for the prevention and treatment of inflammatory disorders
Dohil et al. Understanding intestinal cysteamine bitartrate absorption
ES2689906T3 (es) Meglumina para reducir los niveles altos de triglicéridos
Wernicke et al. Antidepressants: duloxetine at doses of 60 mg QD and 60 mg BID is effective in treatment of diabetic neuropathic pain (DNP)
JP2017533967A (ja) システアミン組成物を用いるハンチントン病の処置方法
CN104619316B (zh) 用于降低n-氧化三甲胺水平的药物组合物
CN113476432B (zh) J147在制备治疗和/或预防色素增多性疾病的药物/化妆品的用途
Szałek et al. The pharmacokinetics of oral oxycodone in patients after total gastric resection.
US12533394B2 (en) Compositions and methods for treating metabolic disorders
Eldalal et al. The Correlation between Pharmacological Param-eters of Oxycodone and Opioid Epidemic
CN118453879B (zh) 恩杂鲁胺与铜离子载体联合在制备前列腺癌治疗药物中的应用
US20230364031A1 (en) Treatment of brain copper disorders
JP5060136B2 (ja) 血管内皮細胞接着分子の発現抑制及び単球遊走因子の産生抑制剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination